HUTCHMED (China) (HCM) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Phibro Animal Health (PAHC) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 3.0% versus a loss of 12.0%. Over five years, PAHC leads with a +75.7% price change compared with -56.3% for HCM. HUTCHMED (China) is the larger company by market cap ($2.45 billion vs $1.56 billion), about 1.6 times the size, while Phibro Animal Health is growing revenue faster (+17.1% vs -13.0%).
On valuation, Phibro Animal Health trades at a lower forward P/E (10.0x vs 54.4x for HUTCHMED (China)). Phibro Animal Health pays a dividend yielding 1.25%, while HUTCHMED (China) does not currently pay one. HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus 6.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | PAHC |
|---|---|---|
| Share price | $14.10 | $38.30 |
| Market cap | $2.45B | $1.56B |
| 1-day change | +3.15% | +2.41% |
| YTD return | +5.78% | +2.52% |
| 1-year return | -11.99% | +3.04% |
| 5-year return | -56.35% | +75.69% |
| P/E ratio (TTM) | 141.00 | 15.76 |
| Forward P/E | 54.40 | 9.97 |
| EPS (TTM) | $0.10 | $2.43 |
| Dividend yield | 0.00% | 1.25% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $548.51M | $1.52B |
| Revenue growth (YoY) | -12.96% | +17.12% |
| Net income (latest FY) | $456.91M | $99.72M |
| Gross margin | 38.68% | 33.76% |
| Operating margin | -7.14% | 12.81% |
| Net margin | 83.30% | 6.57% |
| 52-week high | $16.33 | $60.08 |
| 52-week low | $9.77 | $28.25 |
| Distance from 52-week high | -13.66% | -36.25% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +56.10% | +14.88% |
| Average volume | 68.22K | 231.66K |
| Shares outstanding | 173.81M | 21.11M |
| Employees | 1,790 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PAHC has outperformed HCM by 15.0 percentage points over the past year.
- HUTCHMED (China) trades at a higher earnings multiple (141.0x vs 15.8x trailing P/E).
- Phibro Animal Health offers a meaningfully higher dividend yield (1.25% vs 0.00%).
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus 6.6 cents for Phibro Animal Health.
- Phibro Animal Health grew revenue faster in its latest fiscal year (+17.12% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
HCM vs PAHC FAQ
Which is bigger, HUTCHMED (China) or Phibro Animal Health?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.45B compared with $1.56B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, HCM or PAHC?
PAHC returned +3.04% over the past 12 months, compared with -11.99% for HCM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HCM or PAHC?
PAHC has the lower trailing P/E at 15.8, versus 141.0 for HCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, HUTCHMED (China) or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.25%, while HUTCHMED (China) does not currently pay a regular dividend.
Are HUTCHMED (China) and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.